Compare SEVN & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEVN | IVVD |
|---|---|---|
| Founded | 1986 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.4M | 201.9M |
| IPO Year | 2008 | 2021 |
| Metric | SEVN | IVVD |
|---|---|---|
| Price | $7.65 | $0.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $10.50 | $8.75 |
| AVG Volume (30 Days) | 159.5K | ★ 3.3M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 13.90% | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ 0.19 | N/A |
| Revenue | $29,383,000.00 | ★ $53,426,000.00 |
| Revenue This Year | $27.75 | $61.57 |
| Revenue Next Year | $4.06 | $41.42 |
| P/E Ratio | $40.11 | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $7.37 | $0.49 |
| 52 Week High | $11.15 | $3.07 |
| Indicator | SEVN | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 33.16 |
| Support Level | N/A | N/A |
| Resistance Level | N/A | $1.01 |
| Average True Range (ATR) | 0.00 | 0.05 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 14.31 |
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.